Cargando…
Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study
BACKGROUND: China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The objective of this paper is to evaluate the current status of anti-TB dr...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720996/ https://www.ncbi.nlm.nih.gov/pubmed/26792535 http://dx.doi.org/10.1186/s40249-016-0098-9 |
_version_ | 1782411156531445760 |
---|---|
author | Huang, Fei Zhang, Hui Lv, Qing Sato, Kaori D. Qu, Yan Huan, Shitong Cheng, Jun Zhao, Fei Wang, Lixia |
author_facet | Huang, Fei Zhang, Hui Lv, Qing Sato, Kaori D. Qu, Yan Huan, Shitong Cheng, Jun Zhao, Fei Wang, Lixia |
author_sort | Huang, Fei |
collection | PubMed |
description | BACKGROUND: China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The objective of this paper is to evaluate the current status of anti-TB drug use for newly diagnosed pulmonary TB inpatients treated in prefecture- and county-level designated hospitals. METHODS: Three prefecture-level hospitals and nine county-level hospitals were selected for the study. All newly diagnosed pulmonary TB inpatient medical records from 2012 were reviewed and doubly examined by two national senior physicians. The rational use of anti-TB drugs was evaluated based on criteria in line with WHO’s guideline. RESULTS: Of the 2,060 total treatment regimens for TB, 53.1 % were found to be rational (1093/2060). The percentages in prefecture-level and county-level hospitals were 50.3 % (761/1513) and 60.7 % (332/547), respectively. The difference between the two levels of hospitals was statistically significant (Chi-square value = 17.44, P < 0.01). The percentages of rational treatment regimens for first-time hospitalizations and for two or more hospitalizations were 59.5 % (983/1653) and 27.0 % (110/407), respectively, with a statistically significant difference (Chi-square value = 138.00, P < 0.01). The overall use of second-line drugs (SLD) was 54.9 % (1131/2060). The percentages for prefecture-level and county-level hospitals were 50.6 % (766/1513) and 66.7 % (365/547), respectively. A statistically significant difference was found (Chi-square value = 42.06, P < 0.01). The use of SLD for inpatients hospitalized once and inpatients hospitalized twice or more was 58.4 % (966/1653) and 40.5 % (165/407), respectively, with a statistically significant difference (Chi-square value = 42.26, P < 0.01). CONCLUSIONS: Half of inpatients might be treated with irrational regimens, and the use of SLD was more appropriately dispensed in city-level hospitals than in county-level hospitals. Trainings and guidelines for health personnel, supervision led by health authorities and increased investment to designated hospitals may help to improve the rational use of anti-TB drugs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-016-0098-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4720996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47209962016-01-22 Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study Huang, Fei Zhang, Hui Lv, Qing Sato, Kaori D. Qu, Yan Huan, Shitong Cheng, Jun Zhao, Fei Wang, Lixia Infect Dis Poverty Research Article BACKGROUND: China’s national tuberculosis control program (NTP) provides free, first-line anti-tuberculosis (TB) drugs to pulmonary TB patients. This treatment regimen follows the World Health Organization’s (WHO) guideline. The objective of this paper is to evaluate the current status of anti-TB drug use for newly diagnosed pulmonary TB inpatients treated in prefecture- and county-level designated hospitals. METHODS: Three prefecture-level hospitals and nine county-level hospitals were selected for the study. All newly diagnosed pulmonary TB inpatient medical records from 2012 were reviewed and doubly examined by two national senior physicians. The rational use of anti-TB drugs was evaluated based on criteria in line with WHO’s guideline. RESULTS: Of the 2,060 total treatment regimens for TB, 53.1 % were found to be rational (1093/2060). The percentages in prefecture-level and county-level hospitals were 50.3 % (761/1513) and 60.7 % (332/547), respectively. The difference between the two levels of hospitals was statistically significant (Chi-square value = 17.44, P < 0.01). The percentages of rational treatment regimens for first-time hospitalizations and for two or more hospitalizations were 59.5 % (983/1653) and 27.0 % (110/407), respectively, with a statistically significant difference (Chi-square value = 138.00, P < 0.01). The overall use of second-line drugs (SLD) was 54.9 % (1131/2060). The percentages for prefecture-level and county-level hospitals were 50.6 % (766/1513) and 66.7 % (365/547), respectively. A statistically significant difference was found (Chi-square value = 42.06, P < 0.01). The use of SLD for inpatients hospitalized once and inpatients hospitalized twice or more was 58.4 % (966/1653) and 40.5 % (165/407), respectively, with a statistically significant difference (Chi-square value = 42.26, P < 0.01). CONCLUSIONS: Half of inpatients might be treated with irrational regimens, and the use of SLD was more appropriately dispensed in city-level hospitals than in county-level hospitals. Trainings and guidelines for health personnel, supervision led by health authorities and increased investment to designated hospitals may help to improve the rational use of anti-TB drugs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40249-016-0098-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-21 /pmc/articles/PMC4720996/ /pubmed/26792535 http://dx.doi.org/10.1186/s40249-016-0098-9 Text en © Huang et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Huang, Fei Zhang, Hui Lv, Qing Sato, Kaori D. Qu, Yan Huan, Shitong Cheng, Jun Zhao, Fei Wang, Lixia Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study |
title | Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study |
title_full | Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study |
title_fullStr | Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study |
title_full_unstemmed | Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study |
title_short | Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study |
title_sort | use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in china: a retrospective study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720996/ https://www.ncbi.nlm.nih.gov/pubmed/26792535 http://dx.doi.org/10.1186/s40249-016-0098-9 |
work_keys_str_mv | AT huangfei useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT zhanghui useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT lvqing useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT satokaorid useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT quyan useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT huanshitong useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT chengjun useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT zhaofei useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy AT wanglixia useofantituberculosisdrugsamongnewlydiagnosedpulmonarytuberculosisinpatientsinchinaaretrospectivestudy |